Peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes

被引:24
|
作者
Lee, Byung Cheol
Lee, Hye-jung
Chung, Joo-Ho [1 ]
机构
[1] Kyung Hee Univ, Dept Oriental Internal Med, Seoul, South Korea
[2] Kyung Hee Univ, Dept Acupuncture & Meridian, Seoul, South Korea
[3] Kyung Hee Univ, Coll Med, Kohwang Med Inst, Seoul 130701, South Korea
[4] Kyung Hee Univ, Coll Med, Dept Pharmacol, Seoul 130701, South Korea
关键词
stroke; ischemic; type; 2; diabetes; peroxisome proliferator-activated receptor (PPAR)-gamma 2; polymorphism;
D O I
10.1016/j.neulet.2006.08.024
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Peroxisome proliferator-activated receptor (PPAR)-gamma(2) has important effects to insulin sensitivity, atherosclerosis, inflammation and endothelial cell function. Through these effects, PPAR-gamma(2) might be involved with the ischemic stroke in type 2 diabetes. To determine the role of PPAR-gamma(2) in genetic susceptibility to ischemic stroke in type 2 diabetes, we genotyped 302 ischemic stroke patients, 283 healthy controls and 141 type 2 diabetic patients without ischemic stroke (diabetes duration > 10 years) for PPAR-gamma(2) Pro12Ala polymorphism by polymerase chain reaction-restriction fragment length polymorphism methods. PPAR-gamma 2 Pro/Ala genotype were lower in ischemic stroke patients than those observed in the control group (4.0% vs. 9.9%. OR = 0.38, P = 0.0046), and it were associated with the incidence of ischemic stroke in the multivariate analysis (OR = 0.43, P = 0.025). Genotypic analysis revealed that ischemic stroke patients with type 2 diabetes displayed a great lower prevalence of the Pro/Ala genotype (2.3%) than controls (9.9%) (OR = 0.21, P = 0.0047). And Pro/Ala genotype of type 2 diabetes patients with ischemic stroke were lower than type 2 diabetes patients without ischemic stroke (2.3% vs. 8.5%, OR = 0.25, P = 0.0321), however the significant association with ischemic stroke was not detected in the multivariate analysis (OR = 0.27 P = 0.051). These results suggest that the Pro/Ala genotype of PPAR-gamma 2 Pro12Ala polymorphism may be associated with reduced risk for ischemic stroke, and the possibility that it might have a protective effect for ischemic stroke with type 2 diabetes. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:141 / 145
页数:5
相关论文
共 50 条
  • [31] Association between Peroxisome Proliferator-Activated Receptor Pro12Ala Polymorphism and Gestational Diabetes Mellitus
    Mao, Di
    Li, Ping
    Lin, Shuo
    Li, Ling
    Fan, Jianhui
    DIABETES, 2017, 66 : A647 - A647
  • [32] Peroxisome proliferator-activated receptor γ Pro12 ala polymorphism and risk of cerebral stroke in type 2 diabetes mellitus egyptian patients
    El-Farahaty, Reham M. M.
    Fouda, Osama
    EL-Deasty, Amany
    El-Gilany, Abdel-Hady
    Saied, Narmin
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2023, 22 (01) : 415 - 422
  • [33] The peroxisome proliferator-activated receptor-γ 2 (PPAR-γ 2) Pro12Ala polymorphism is associated with decreased risk of advanced diabetic nephropathy in patients with type 2 diabetes mellitus (DM2)
    Caramori, ML
    Canani, LH
    Costa, L
    Gross, JL
    DIABETES, 2003, 52 : A49 - A49
  • [34] Effects of peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism on body fat distribution in female Korean subjects
    Kim, KS
    Choi, SM
    Shin, SU
    Yang, HS
    Yoon, Y
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2004, 53 (12): : 1538 - 1543
  • [35] Association of peroxisome proliferator-activated receptor γ Pro12Ala gene polymorphism with type 2 diabetic nephropathy risk in Caucasian population
    Zhou, Tian-Biao
    Guo, Xue-Feng
    Yin, Sheng-Sheng
    JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, 2014, 34 (03) : 180 - 184
  • [36] Peroxisome proliferator-activated receptor γ Pro12 ala polymorphism and risk of cerebral stroke in type 2 diabetes mellitus egyptian patients
    Reham M. El-Farahaty
    Osama Fouda
    Amany EL-Deasty
    Abdel-Hady El-Gilany
    Narmin Saied
    Journal of Diabetes & Metabolic Disorders, 2023, 22 : 415 - 422
  • [37] Increased insulin clearance in peroxisome proliferator-activated receptor γ2 Pro12Ala
    Tschritter, O
    Fritsche, A
    Stefan, N
    Haap, M
    Thamer, C
    Bachmann, O
    Dahl, D
    Maerker, E
    Teigeler, A
    Machicao, F
    Häring, H
    Stumvoll, M
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2003, 52 (06): : 778 - 783
  • [38] PRO12ALA GENE POLYMORPHISM IN THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AS A RISK FACTOR FOR THE ONSET OF TYPE 2 DIABETES MELLITUS IN THE SERBIAN POPULATION
    Soskic, Sanja
    Stankovic, Aleksandra
    Djuric, Tamara
    Zivkovic, Maja
    Ristic, P.
    Andjelkovic, Z.
    Sumarac-Dumanovic, Mirjana
    Alavantic, D.
    ARCHIVES OF BIOLOGICAL SCIENCES, 2010, 62 (02) : 263 - 270
  • [39] Peroxisome proliferator-activated receptor-γ2 (PPARγ) polymorphism Pro12Ala and diabetic nephropathy in Type 1 diabetic patients in the FinnDiane Study
    Forsblom, CM
    Fröjdö, S
    Parkkonen, M
    Pettersson-Fernholm, K
    Fagerudd, J
    Groop, PH
    DIABETOLOGIA, 2003, 46 : A334 - A335
  • [40] Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-γ2 in Korean diabetic and obese subjects
    Oh, EY
    Min, KM
    Chung, JH
    Min, YK
    Lee, MS
    Kim, KW
    Lee, MK
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (05): : 1801 - 1804